Helicobacter Pylori and Vonoprazan Dual Therapy

Phase 4

Completed

• Conditions: Helicobacter Pylori

• Registration Number: NCT05649709
• Lead Sponsor: The First Affiliated Hospital of Nanchang University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-27
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 504

Inclusion Criteria

Inclusion Criteria:<br><br> - Consecutive H. pylori-infected subjects ages from 18 to 70 without eradication<br> history<br><br>Exclusion Criteria:<br><br> - allergy to amoxicillin or vonoprazan;<br><br> - acute upper gastrointestinal bleeding, gastric cancer or other tumors,<br> Zollinger-Ellison syndrome, history of gastric surgery;<br><br> - serious illness including neurological, cardiovascular, pulmonary, hepatic, renal,<br> metabolic, gastrointestinal, urological, endocrinological or hematological<br> disorders;<br><br> - pregnancy or breast feeding;<br><br> - proton pump inhibitors and antibiotics use within one month;<br><br> - not willing to participate in the study

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of VA dual therapy

Secondary Outcome Measures

Name	Time	Method
treatment-emergent adverse events;compliance;resistance of antibiotics;the alteration of gut microbiota